TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB04615

Activity

Antibacterial

Activity_category_statistics

Anti-infective peptides

Database_Source

AntiBP3 Peptipedia

Sequence_Type

standard

Has_Modification No

Description A 40-aa standard natural antibacterial peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.

Sequence

GFGCNGPWSEDDLRCHRHCKSIKGYRGGYCAKGGFVCKCY

FASTA

>TPDB04615|Antibacterial|length=40
GFGCNGPWSEDDLRCHRHCKSIKGYRGGYCAKGGFVCKCY

Formula C192H285N59O53S6

Absent Amino Acids QMT

Common Amino Acids G

Mass 4460.10

PI 8.57

Basic Residues 9

Acidic Residues 3

Hydrophobic Residues 10

Net Charge +4

Boman Index 4.66

Hydrophobicity -0.645

Aliphatic Index 29.25

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 10345

Absorbance 280nm 231.95

Polar Residues 12

number

1

A

3

R

1

N

2

D

6

C

1

E

0

Q

8

G

2

H

1

I

1

L

4

K

0

M

2

F

1

P

2

S

0

T

1

W

3

Y

1

V

Amino Acid Distribution

A: 1 R: 3 N: 1 D: 2 C: 6 E: 1 Q: 0 G: 8 H: 2 I: 1 L: 1 K: 4 M: 0 F: 2 P: 1 S: 2 T: 0 W: 1 Y: 3 V: 1

Length

40

Formula

C192H285N59O53S6

Mass

4460.10

PI

8.57

Net Charge

+4

Boman Index

4.66

Hydrophobicity

-0.645

Evidence 1 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 2-64 µg/mL

Target

Target Organism

Staphylococcus aureus ATCC 25923 or ATCC 43300 or E48 or CVCC 546 or CAAS-FRI-2023-01 or CAAS-FRI-2023-02 and 8 clinical strains

Source & Reference

Database Source NA

Other

Evidence Text

active against S. aureus ATCC 25923 or ATCC 43300 or E48 or CVCC 546 or CAAS-FRI-2023-01 or CAAS-FRI-2023-02 and 8 clinical strains (MIC 2-64 ug/ml), S. epidermidis ATCC 12228 or ATCC 35984 (MIC 4-8 ug/ml), S. dysgalactiae CVCC 3938 (MIC

Evidence 2 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 4-8 µg/mL

Target

Target Organism Staphylococcus epidermidis ATCC 12228 or ATCC 35984

Source & Reference

Database Source NA

Other

Evidence Text

CVCC 546 or CAAS-FRI-2023-01 or CAAS-FRI-2023-02 and 8 clinical strains (MIC 2-64 ug/ml), S. epidermidis ATCC 12228 or ATCC 35984 (MIC 4-8 ug/ml), S. dysgalactiae CVCC 3938 (MIC 4 ug/ml), S. agalactiae ATCC 13813 or CAU-FRI-2022-01 or

Evidence 3 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 4 µg/mL

Target

Target Organism S. dysgalactiae CVCC 3938

Source & Reference

Database Source NA

Other

Evidence Text

inical strains (MIC 2-64 ug/ml), S. epidermidis ATCC 12228 or ATCC 35984 (MIC 4-8 ug/ml), S. dysgalactiae CVCC 3938 (MIC 4 ug/ml), S. agalactiae ATCC 13813 or CAU-FRI-2022-01 or CAU-FRI-2022-02 (MIC 4 ug/ml). MBC are 2-

Evidence 4 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 4 µg/mL

Target

Target Organism Streptococcus agalactiae ATCC 13813 or CAU-FRI-2022-01 or CAU-FRI-2022-02

Source & Reference

Database Source NA

Other

Evidence Text

rmidis ATCC 12228 or ATCC 35984 (MIC 4-8 ug/ml), S. dysgalactiae CVCC 3938 (MIC 4 ug/ml), S. agalactiae ATCC 13813 or CAU-FRI-2022-01 or CAU-FRI-2022-02 (MIC 4 ug/ml). MBC are 2-8 fold higher. rapid killing, including intracellular S. aureus.